Ettl J, Im SA, Ro J, Masuda N, et al. Hematologic adverse events following palbociclib dose reduction in patients with
hormone receptor-positive/human epidermal growth factor receptor 2-negative
advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Res 2020;22:27.
PMID: 32164785